Kim Kjøller's decision to leave the role of Executive Vice President Global Research&Development at Leo Pharma in favor of a CEO position in a minor biotech firm partly owes to his vision of creating a new frontrunner in the Danish pharmaceutical industry.
Kjøller tells MedWatch this in the wake of Tuesday's announcement that he is leaving Leo Pharma to become the CEO of the biotech company Union Therapeutics.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.